Estimating Infection Attack Rates and Severity in Real Time during an Influenza Pandemic: Analysis of Serial Cross-Sectional Serologic Surveillance Data

English version České info

Background:
In an emerging influenza pandemic, estimating severity (the probability of a severe outcome, such as hospitalization, if infected) is a public health priority. As many influenza infections are subclinical, sero-surveillance is needed to allow reliable real-time estimates of infection attack rate (IAR) and severity.

Methods and Findings:
We tested 14,766 sera collected during the first wave of the 2009 pandemic in Hong Kong using viral microneutralization. We estimated IAR and infection-hospitalization probability (IHP) from the serial cross-sectional serologic data and hospitalization data. Had our serologic data been available weekly in real time, we would have obtained reliable IHP estimates 1 wk after, 1–2 wk before, and 3 wk after epidemic peak for individuals aged 5–14 y, 15–29 y, and 30–59 y. The ratio of IAR to pre-existing seroprevalence, which decreased with age, was a major determinant for the timeliness of reliable estimates. If we began sero-surveillance 3 wk after community transmission was confirmed, with 150, 350, and 500 specimens per week for individuals aged 5–14 y, 15–19 y, and 20–29 y, respectively, we would have obtained reliable IHP estimates for these age groups 4 wk before the peak. For 30–59 y olds, even 800 specimens per week would not have generated reliable estimates until the peak because the ratio of IAR to pre-existing seroprevalence for this age group was low. The performance of serial cross-sectional sero-surveillance substantially deteriorates if test specificity is not near 100% or pre-existing seroprevalence is not near zero. These potential limitations could be mitigated by choosing a higher titer cutoff for seropositivity. If the epidemic doubling time is longer than 6 d, then serial cross-sectional sero-surveillance with 300 specimens per week would yield reliable estimates when IAR reaches around 6%–10%.

Conclusions:
Serial cross-sectional serologic data together with clinical surveillance data can allow reliable real-time estimates of IAR and severity in an emerging pandemic. Sero-surveillance for pandemics should be considered.

: Please see later in the article for the Editors' Summary

Vyšlo v časopise: Estimating Infection Attack Rates and Severity in Real Time during an Influenza Pandemic: Analysis of Serial Cross-Sectional Serologic Surveillance Data. PLoS Med 8(10): e32767. doi:10.1371/journal.pmed.1001103
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1001103

Souhrn

Zdroje

1. LipsitchMRileySCauchemezSGhaniACFergusonNM 2009 Managing and reducing uncertainty in an emerging influenza pandemic. N Engl J Med 361 112 115

2. FraserCDonnellyCACauchemezSHanageWPVan KerkhoveMD 2009 Pandemic potential of a strain of influenza A (H1N1): early findings. Science 324 1557 1561

3. Van KerkhoveMDAsikainenTBeckerNGBjorgeSDesenclosJC 2009 Studies needed to address public health challenges of the 2009 H1N1 influenza pandemic: insights from modeling. PLoS Med 7 e1000275 doi:10.1371/journal.pmed.1000275

4. WhiteLFWallingaJFinelliLReedCRileyS 2009 Estimation of the reproductive number and the serial interval in early phase of the 2009 influenza A/H1N1 pandemic in the USA. Influenza Other Respi Viruses 3 267 276

5. YangYSugimotoJDHalloranMEBastaNEChaoDL 2009 The transmissibility and control of pandemic influenza A (H1N1) virus. Science 326 729 733

6. PresanisAMDe AngelisDHagyAReedC The New York City Swine Flu Investigation Team 2009 The severity of pandemic H1N1 influenza in the United States, from April to July 2009: a Bayesian analysis. PLoS Medicine 6 e1000207 doi:10.1371/journal.pmed.1000207

7. WuJTMaESKLeeCKChuDKWHoPL 2010 The infection attack rate and severity of 2009 pandemic influenza (H1N1) in Hong Kong. Clin Infect Dis 51 1184 1191

8. RileySKwokKOWuKMNingDYCowlingBJ 2011 Epidemiological characteristics of 2009 (H1N1) pandemic influenza based on paired sera from a longitudinal community cohort study. PLoS Med 8 e1000442 doi:10.1371/journal.pmed.1000442

9. BaguelinMHoschlerKStanfordEWaightPHardelidP 2011 Age-specific incidence of A/H1N1 2009 influenza infection in England from sequential antibody prevalence data using likelihood-based estimation. PLoS ONE 6 e17074 doi:10.1371/journal.pone.0017074

10. HardelidPAndrewsNJHoschlerKStanfordEBaguelinM 2011 Assessment of baseline age-specific antibody prevalence and incidence of infection to novel influenza A/H1N1 2009. Health Technol Assess 14 115 192

11. CowlingBJLauMSHoLMChuangSKTsangT 2010 The effective reproduction number of pandemic influenza: prospective estimation. Epidemiology 21 842 846

12. WuJTCowlingBJLauEHIpDKHoLM 2010 School closure and mitigation of pandemic (H1N1) 2009, Hong Kong. Emerg Infect Dis 16 538 541

13. World Health Organization Global Influenza Surveillance Network 2011 Manual for the laboratory diagnosis and virological surveillance of influenza Geneva World Health Organization

14. VeguillaVHancockKSchifferJGargiulloPLuX 2011 Sensitivity and specificity of serologic assays for detection of human infection with 2009 pandemic H1N1 virus in U.S. populations. J Clin Microbiol 49 2210 2215

15. ChenMILeeVJLimWYBarrIGLinRT 2010 2009 influenza A(H1N1) seroconversion rates and risk factors among distinct adult cohorts in Singapore. JAMA 303 1383 1391

16. MillerEHoschlerKHardelidPStanfordEAndrewsN 2010 Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-sectional serological study. Lancet 375 1100 1108

17. GoldsteinEDushoffJMaJPlotkinJBEarnDJ 2009 Reconstructing influenza incidence by deconvolution of daily mortality time series. Proc Natl Acad Sci U S A 106 21825 21829

18. PapenburgJBazMHamelinMERheaumeCCarbonneauJ 2011 Evaluation of serological diagnostic methods for the 2009 pandemic influenza A (H1N1) virus. Clin Vaccine Immunol 18 520 522

19. SvenssonA 2007 A note on generation times in epidemic models. Math Biosci 208 300 311

20. WearingHJRohaniPKeelingMJ 2005 Appropriate models for the management of infectious diseases. PLoS Med 2 e174 doi:10.1371/journal.pmed.0020174

21. HungIFToKKLeeCKLinCKChanJF 2010 Effect of clinical and virological parameters on the level of neutralizing antibody against pandemic influenza A virus H1N1 2009. Clin Infect Dis 51 274 279

22. StephensonINicholsonKGGluckRMischlerRNewmanRW 2003 Safety and antigenicity of whole virus and subunit influenza A/Hong Kong/1073/99 (H9N2) vaccine in healthy adults: phase I randomised trial. Lancet 362 1959 1966

23. CowlingBJChanKHFangVJLauLLSoHC 2010 Comparative epidemiology of pandemic and seasonal influenza A in households. N Engl J Med 362 2175 2184

24. FinebergHVAavitslandPAditamaTBinoSCarmoEH 2011 Implementation of the international health regulations (2005): report of the Review Committee on the Functioning of the International Health Regulations (2005) and on Pandemic Influenza A (H1N1) 2009. Geneva: World Health Organization. Available: http://apps.who.int/gb/ebwha/pdf_files/WHA64/A64_10-en.pdf. Accessed 6 September 2011

25. BaguelinMHoekAJJitMFlascheSWhitePJ 2010 Vaccination against pandemic influenza A/H1N1v in England: a real-time economic evaluation. Vaccine 28 2370 2384

26. OngJBChenMICookARLeeHCLeeVJ 2010 Real-time epidemic monitoring and forecasting of H1N1-2009 using influenza-like illness from general practice and family doctor clinics in Singapore. PLoS ONE 5 e10036 doi:10.1371/journal.pone.0010036

27. 2010 Seroepidemiological studies of pandemic influenza A (H1N1) 2009 virus. Wkly Epidemiol Rec 85 229 235

28. BandaranayakeDHuangQSBissieloAWoodTMackerethG 2010 Risk factors and immunity in a nationally representative population following the 2009 influenza A(H1N1) pandemic. PLoS ONE 5 e13211 doi:10.1371/journal.pone.0013211

29. MakGCChoyPWLeeWYWongAHNgKC 2010 Sero-immunity and serologic response to pandemic influenza A (H1N1) 2009 virus in Hong Kong. J Med Virol 82 1809 1815

30. BuchyPVongSChuSGarciaJMHienTT Kinetics of neutralizing antibodies in patients naturally infected by H5N1 virus. PLoS ONE 5 e10864 doi:10.1371/journal.pone.0010864

31. TogoYSchwartzARTominagaSHornickRB 1972 Cyclooctylamine in the prevention of experimental human influenza. JAMA 220 837 841